Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on Overweight and the Gut Microbiota in Humans: Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
What this study found
The probiotic intervention produced modest but significant reductions in adiposity over 12 weeks. In the active arm, body weight decreased by -0.47 ± 0.29 kg (p = 0.001), BMI by -0.15 ± 0.1 kg/m2 (p < 0.001), waist circumference by -0.41 ± 0.37 cm (p = 0.007), body fat mass by -0.28 ± 0.24 kg (p = 0.043), lean body mass by -0.18 ± 0.25 kg (p = 0.032), and visceral fat area by -1.67 ± 1.44 cm2 (p = 0.025). Adiponectin increased by 133.33 ± 150.47 ng/mL (p = 0.046), while hip circumference, leptin, insulin, hs-CRP, and the reported lipid measures did not show clear significant benefit. The…
- Study & population
- Randomized, double-blind, placebo-controlled trial in healthy Korean adults who were overweight or obese.
- Intervention
- Participants in the active arm took 1 oral probiotic capsule daily after breakfast for 12 weeks.
- Key limitation
- The active arm was small (n = 30) and the intervention lasted only 12 weeks, limiting precision and durability assessment.
View source
Open PDFOriginal abstract
Obesity and overweight are closely related to diet, and the gut microbiota play an important role in body weight and human health. The aim of this study was to explore how Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 supplementation alleviate obesity by modulating the human gut microbiome. A randomized, double-blind, placebo-controlled study was conducted on 72 individuals with overweight. Over a 12-week period, probiotic groups consumed 1 × 1010 colony-forming units of HY7601 and KY1032, whereas the placebo group consumed the same product without probiotics. After treatment, the probiotic group displayed a reduction in body weight (p < 0.001), visceral fat mass (p < 0.025), and waist circumference (p < 0.007), and an increase in adiponectin (p < 0.046), compared with the placebo group. Additionally, HY7601 and KY1032 supplementation modulated bacterial gut microbiota characteristics and beta diversity by increasing Bifidobacteriaceae and Akkermansiaceae and decreasing Prevotellaceae and Selenomonadaceae. In summary, HY7601 and KY1032 probiotics exert anti-obesity effects by regulating the gut microbiota; hence, they have therapeutic potential for preventing or alleviating obesity and living with overweight.